 |
|
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis
A Randomized Controlled Trial
Steven T. Harris, MD;
Nelson B. Watts, MD;
Harry K. Genant, MD;
Clark D. McKeever, MD;
Thomas Hangartner, PhD;
Michael Keller, MD;
Charles H. Chesnut III, MD;
Jacques Brown, MD;
Erik F. Eriksen, MD;
Mohammad S. Hoseyni, PhD;
Douglas W. Axelrod, MD, PhD;
Paul D. Miller, MD;
for the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group
JAMA. 1999;282:1344-1352.
ABSTRACT
| |
Context Risedronate, a potent bisphosphonate, has been shown to be effective in the treatment of Paget disease of bone and other metabolic bone diseases but, to our knowledge, it has not been evaluated in the treatment of established postmenopausal osteoporosis.
Objective To test the efficacy and safety of daily treatment with risedronate to reduce the risk of vertebral and other fractures in postmenopausal women with established osteoporosis.
Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial of 2458 ambulatory postmenopausal women younger than 85 years with at least 1 vertebral fracture at baseline who were enrolled at 1 of 110 centers in North America conducted between December 1993 and January 1998.
Interventions Subjects were randomly assigned to receive oral treatment for 3 years with risedronate (2.5 or 5 mg/d) or placebo. All subjects received calcium, 1000 mg/d. Vitamin D (cholecalciferol, up to 500 IU/d) was provided if baseline levels of 25-hydroxyvitamin D were low.
Main Outcome Measures Incidence of new vertebral fractures as detected by quantitative and semiquantitative assessments of radiographs; incidence of radiographically confirmed nonvertebral fractures and change from baseline in bone mineral density as determined by dual x-ray absorptiometry.
Results The 2.5 mg/d of risedronate arm was discontinued after 1 year; in the placebo and 5 mg/d of risedronate arms, 450 and 489 subjects, respectively, completed all 3 years of the trial. Treatment with 5 mg/d of risedronate, compared with placebo, decreased the cumulative incidence of new vertebral fractures by 41% (95% confidence interval [CI], 18%-58%) over 3 years (11.3% vs 16.3%;P=.003). A fracture reduction of 65% (95% CI, 38%-81%) was observed after the first year (2.4% vs 6.4%; P<.001). The cumulative incidence of nonvertebral fractures over 3 years was reduced by 39% (95% CI, 6%-61%) (5.2% vs 8.4%; P=.02). Bone mineral density increased significantly compared with placebo at the lumbar spine (5.4% vs 1.1%), femoral neck (1.6% vs -1.2%), femoral trochanter (3.3% vs -0.7%), and midshaft of the radius (0.2% vs -1.4%). Bone formed during risedronate treatment was histologically normal. The overall safety profile of risedronate, including gastrointestinal safety, was similar to that of placebo.
Conclusions These data suggest that risedronate therapy is effective and well tolerated in the treatment of women with established postmenopausal osteoporosis.
INTRODUCTION
Declining estrogen levels at menopause result in increased bone turnover and a loss of bone mass, with subsequent increases in bone fragility and the risk of bone fracture. Vertebral fracture, in particular, is a common consequence of osteoporosis and may be considered the hallmark fracture for osteoporosis in postmenopausal women.1 Because of the high frequency of vertebral fractures in patients with postmenopausal osteoporosis, clinical trials of osteoporosis therapies now typically assess the effects of treatment on vertebral fracture incidence as the primary end point. Prevention of nonvertebral fractures is another important goal of treatment because of the pain and disability associated with these fractures.
Several therapies have demonstrated antifracture efficacy in the treatment of established postmenopausal osteoporosis. Hormone replacement therapy reduced the occurrence of vertebral fracture in a small, prospective trial,2 and a prospective cohort study supports the usefulness of hormone replacement therapy in reducing the progression of disease, even in older women.3 However, sustained benefit requires long-term use of hormones, and few women accept long-term treatment due to poor tolerability and fear of breast cancer.4-5 Both raloxifene and calcitonin have been shown to modestly increase bone mineral density (BMD) and decrease the incidence of vertebral fracture; however, neither therapy has demonstrated significant effects in reducing nonvertebral fractures.6-8 Other bisphosphonates have demonstrated efficacy in prevention of vertebral fracture, although the interpretation of the fracture results in these studies is complicated by the pooling of dosage groups,9 changing of dosage during the study,10 and analysis of subpopulations.11 Although alendronate reduced the incidence of all clinical fractures in a population of patients with a history of vertebral fractures,10 a recent study in more than 4000 subjects with low BMD and no history of vertebral fracture failed to demonstrate this benefit, except in a subpopulation of women with low hip bone density.12 Gastrointestinal tract adverse effects are a concern with some bisphosphonates.13-15 Although the incidence of such adverse effects has been low, upper gastrointestinal tract adverse events such as erosive esophagitis have been reported.14-15
Risedronate (chemical name, [1-hydroxy-2-(3-pyridinyl) ethylidene] bis[phosphonic acid] monosodium salt), a pyridinyl bisphosphonate with potent antiresorptive activity, has been shown to be effective for the treatment of Paget disease of bone16-17 and multiple myeloma,18-19 and for the prevention of bone loss in early postmenopause.20 The present study was designed to test the efficacy of daily risedronate treatment in reducing the incidence of vertebral and other fractures in postmenopausal women with a history of vertebral fracture and to evaluate the safety of risedronate therapy in these patients.
METHODS
Protocol
This randomized, double-blind, placebo-controlled, parallel-group study was conducted at 110 study centers in North America between December 1993 and January 1998. Study centers included office-based practices, academic research centers, and regional osteoporosis clinics. All subjects gave written informed consent before enrollment into the study, which was conducted according to the tenets of the Declaration of Helsinki and approved by the appropriate institutional review boards.
Ambulatory women were eligible for the study if they were no older than 85 years, if 5 years had elapsed since natural or surgical menopause, and if they had either 2 or more radiographically identified vertebral fractures (T4-L4, inclusive) or 1 vertebral fracture and low lumbar-spine (L1-L4) BMD (defined as  0.83 g/cm2 [Hologic instrument] or 0.94 g/cm2 [Lunar instrument]). These values represent a T score of -2 (2 SDs below the mean for young adults). Women were excluded if they had conditions that might interfere with the evaluation of spinal bone loss, or if they had received drugs known to affect bone metabolism (such as calcitonin, calcitriol or cholecalciferol supplements within 1 month prior to study entry; anabolic steroids, estrogen or estrogen-related drugs, or progestins within 3 months; or bisphosphonates, fluoride, or subcutaneous estrogen implants within 6 months). Subjects were not excluded specifically because of previous or active gastrointestinal illness or because of concomitant use of aspirin or nonsteroidal anti-inflammatory agents.
Assignment
Participants were stratified based on the number of baseline vertebral fractures (stratum 1, subjects with 1 vertebral fracture and low baseline BMD; stratum 2, subjects with  2 baseline vertebral fractures) and randomly assigned (block size of 3 within each stratum at each study center) to 1 of 3 treatment groups: risedronate, 5 mg/d; risedronate, 2.5 mg/d; or placebo. The randomization schedule was generated by Quintiles Inc (Durham, NC) using SAS version 6.07 (SAS Inc, Cary, NC). Treatment assignments were based on a randomization number issued to each patient after completion of screening procedures.
Blinding
A number of procedures were in place to maintain blinding throughout the study. During the trial, the randomization schedule was held by a clinical research organization (Covance, Princeton, NJ). Covance staff, the investigators, and other research personnel remained blinded to the treatment assignments in the placebo and 5-mg risedronate treatment groups when the 2.5-mg risedronate arm was discontinued. Treatment assignments could be released to the investigators only for reasons of patient safety. To protect the blinding, the placebo and risedronate tablets were physically indistinguishable, and study medication was provided in coded containers labeled with dosing instructions.
Treatment
Subjects were instructed to take the study drug once daily on an empty stomach, 30 to 60 minutes before breakfast, with water, and to remain in an upright position for 1 hour after dosing. All participants received a calcium supplement equivalent to 1000 mg of elemental calcium daily, to be taken with the evening meal. Subjects with low serum 25-hydroxyvitamin D levels at baseline (<40 nmol/L) also received cholecalciferol supplementation (up to 500 IU/d).
Outcome Assessments
Vertebral Fractures
The incidence of new vertebral fractures (fractures in previously normal vertebrae) was expressed as the proportion of subjects with at least 1 incident fracture over 3 years of study. New and worsening vertebral fractures (fractures in previously normal vertebrae and worsening fractures in already fractured vertebrae) were also examined. The sample size of approximately 2400 was based on an expected annual new vertebral fracture incidence of 10% in the placebo group. Assuming a patient withdrawal rate of 50% over 3 years, the study was designed to have at least 90% power to detect a 40% reduction in vertebral fracture risk, with a 2-sided significance level of P=.05.
Lateral thoracic and lumbar spine radiographs were taken at baseline and annually throughout the study. Subjects were enrolled based on a visual assessment of prevalent fractures (T4-L4). For this assessment, a vertebra was considered fractured if the ratio of the anterior or middle vertebral body height to the posterior vertebral body height was 0.8 or less. Quantitative21 and semiquantitative assessments22 were used to identify both prevalent (baseline) and incident vertebral fractures for the purposes of the efficacy determination. An incident new vertebral fracture was defined quantitatively as a loss of 15% or more in the anterior, posterior, or middle vertebral height in a vertebra that was normal at baseline and semiquantitatively as a change from grade 0 (normal) to grades 1 (mild), 2 (moderate), or 3 (severe). A worsening vertebral fracture was recorded if there was a change of 4 mm or more in vertebral height since the previous radiograph or a change in grade in a previously fractured vertebra. An independent radiologist adjudicated discrepancies between the quantitative and semiquantitative methods.23 The radiologists remained blinded to treatment assignment while performing all vertebral fracture assessments.
Bone Mineral Density
Bone mineral density was measured by dual x-ray absorptiometry at baseline and at 6-month intervals throughout the study using Lunar (Lunar Corporation, Madison, Wis) or Hologic (Hologic Inc, Waltham, Mass) densitometers. Scans were analyzed at a central location (Department of Radiology, University of California, San Francisco). Standardized lumbar spine BMD was calculated at baseline to correct for differences in instrumentation.24-25 Femoral neck BMD values obtained using Lunar instruments were adjusted to make them comparable to those obtained using Hologic instruments.24
Other Efficacy Measurements
Radiographically confirmed nonvertebral fractures (defined as fractures of the clavicle, humerus, wrist, pelvis, hip, or leg, whether or not associated with trauma) were recorded throughout the study.
Biochemical markers of bone turnover were assessed in subjects enrolled at a subset of the study centers. Urine was collected for 2 hours after the overnight void on the morning of the office visit, and samples were stored at -70°C until analyzed. Stored samples were analyzed in batches over the course of the study. These measurements were performed at a central laboratory (Quest Diagnostics Inc, San Juan Capistrano, Calif). Bone-specific alkaline phosphatase was determined using the Tandem R-Ostase immunoradiometric assay (Hybritech Inc, San Diego, Calif), and deoxypyridinoline-creatinine ratio was measured by high-pressure liquid chromatography.
Safety Evaluations
Each participant received a physical examination at baseline and at the end of the study. Vital signs and standard hematology and clinical chemistry tests were performed at regular study visits, and adverse events were recorded. Endoscopy was performed at the discretion of the investigator in subjects who reported gastrointestinal complaints.
At selected study centers, iliac crest bone biopsy samples were obtained at baseline and posttreatment following double tetracycline labeling. Histologic and histomorphometric assessments of these samples were performed by a single center in Aarhus, Denmark (E.F.E.). For general bone safety purposes, selected qualitative and quantitative observations are reported here. A full report of these data will be the subject of a future publication.
Statistical Analyses
The planned duration of this study was 3 years. After the study was begun, data from other trials indicated that the 2.5-mg risedronate dose was less effective than the 5-mg dose, and the 2.5-mg risedronate treatment arm in this trial was discontinued by protocol amendment. Therefore, the prospectively defined primary analysis compared the 5-mg risedronate and placebo groups at the 5% significance level. Efficacy analyses were performed on an intention-to-treat basis. In order to facilitate statistical analyses where center was included as a blocking or stratification factor, the 110 investigator sites were pooled by geographic region to form 13 pooled centers prior to unblinding.
At baseline, continuous variables were compared by analysis of variance (ANOVA) with treatment, pooled center, and stratum as factors. Discrete variables were compared by the Cochran-Mantel-Haenszel test, stratified by pooled center and stratum.
For the analysis of fracture incidence (both vertebral and nonvertebral), the placebo and 5-mg risedronate groups were compared on the basis of time to first diagnosed fracture using a stratified log-rank test. A stratified Cox proportional hazards regression model was used to estimate the relative risk of fracture between the 5-mg risedronate and placebo groups. Fracture incidence was calculated using the Kaplan-Meier method.26
Bone mineral density (percentage change from baseline) and bone turnover markers were analyzed by ANOVA. Nonparametric methods were used if model assumptions were not met.
RESULTS
Of approximately 9400 patients screened, lumbar spine radiographs were obtained for about 5800 patients, 35% of whom did not meet the radiologic criteria for study participation. A total of 2458 women met the entry criteria and were enrolled at 110 study centers in North America (Figure 1). All treatment groups had similar demographic characteristics and BMD values at baseline (Table 1). Few subjects (9%) required cholecalciferol supplementation because of low baseline serum levels of 25-hydroxyvitamin D. The majority of subjects were white (96%). Across treatment groups, 1847 subjects (75.7%) completed 1 year of treatment. The 2.5-mg risedronate arm was discontinued by protocol amendment after the first year; 55% of subjects in the placebo group and 60% of subjects in the 5-mg risedronate group completed 3 years of treatment. There were no obvious differences between groups in the reasons for patient withdrawal, and the most common reasons for voluntary withdrawals in all groups were lack of interest, transportation difficulties, and age-related problems (such as the illness of a spouse): these reasons accounted for 83% of all voluntary withdrawals. Examination of a number of parameters, including baseline number of vertebral fractures, lumbar spine T score, age, years since menopause, incidence of adverse events and of vertebral fractures during the trial, and use of concomitant medications, found only 1 apparent difference between patients who withdrew and those who completed the study. Among patients withdrawing from the study, a substantially higher proportion of patients in the placebo group (19.6%) had incident vertebral fractures compared with the proportion of patients in the 5-mg risedronate group (10.6%). More than 85% of subjects in each treatment group took at least 80% of the study medication based on tablet counts.
|
|
|
|
Figure 1. Study Profile and Patient Disposition
|
|
|
|
|
|
|
Table 1. Subject Baseline Characteristics*
|
|
|
Vertebral and Nonvertebral Fractures
The majority of subjects (86%) who experienced vertebral fractures had at least 1 fracture of a previously normal vertebra (a "new" fracture). Over 3 years, there was a statistically significant reduction of 41% (95% confidence interval [CI], 18%-58%) in the risk of new vertebral fractures in the 5-mg risedronate group compared with placebo (P=.003) (Table 2 and Figure 2). The Kaplan-Meier estimates of the incidence over 3 years were 11% in the 5-mg risedronate group and 16% in the placebo group. A significant reduction of 65% (95% CI, 38%-81%) in vertebral fracture risk (2.4% vs 6.4%; P<.001) was seen in the first year of treatment. Approximately 80% of the patients were randomized to stratum 2. This subgroup experienced a 43% reduction in new vertebral fractures over 3 years (P=.003). A similar pattern of response was seen when the proportion of subjects with new and worsening (ie, all incident deformities, whether in previously normal or already deformed vertebrae) vertebral fractures was examined, or when the data were examined using the last observation carried forward for all patients who withdrew. Data are available for the 2.5-mg risedronate group only for the first year of treatment; the effect observed with the 2.5-mg dose was smaller than that seen with the 5-mg dose of risedronate (data not shown).
|
|
|
|
Table 2. Cumulative Incidence of Fractures
|
|
|
|
|
|
|
Figure 2. Incidence of New Vertebral Fractures by Groups Over Time
Asterisk indicates P<.05; dagger, P<.01; and double dagger, P<.001 vs placebo.
|
|
|
The cumulative incidence of nonvertebral fractures over 3 years of treatment was lower by 39% (95% CI, 6%-61%) in the 5-mg risedronate group compared with placebo (5.2% vs 8.4%; P=.02) (Figure 3). The number of patients with fracture in the 5-mg risedronate and placebo groups, respectively, was 14 and 22 at the wrist, 12 and 15 at the hip and/or pelvis, 4 and 10 at the humerus, 4 and 8 at the leg, and 3 and 0 at the clavicle.
|
|
|
|
Figure 3. Incidence of Nonvertebral Fractures by Study Group Over Time
Asterisk indicates P<.05 vs placebo.
|
|
|
Bone Mineral Density
Over 3 years, subjects in the 5-mg risedronate group experienced significant increases in BMD from baseline at the lumbar spine (5.4%), femoral neck (1.6%), and femoral trochanter (3.3%); significant differences compared with baseline and placebo were seen within 6 months (Figure 4). The placebo group showed small but significant(P<.05) changes from baseline in BMD at the lumbar spine (1.1%), femoral neck (-1.2%), and femoral trochanter (-0.7%) over 3 years. At the midshaft of the radius, the 5-mg risedronate group experienced no change in BMD (0.2%), compared with a significant (P<.05) loss in the placebo group of -1.4%.
|
|
|
|
Figure 4. Mean Percent Change From Baseline in Bone Mineral Density
Error bars represent SEM. Measurements at 6, 12, 18, and 30 months were performed at a subset of study centers. In A, P<.05 vs baseline for all time points and groups except the placebo group at 6 months; P<.05 vs placebo for all time points in the 2.5-mg and 5-mg risedronate groups. In B, P<.05 vs baseline for all time points and groups except the placebo group between 0 and 24 months; P<.05 vs placebo for all time points in the 5-mg risedronate group and at 6 months for the 2.5-mg group. In C, P<.05 vs baseline for all time points and groups except the placebo group at 30 months; P<.05 vs placebo for all time points in the 5-mg risedronate group except 6 months.
|
|
|
Markers of Bone Turnover
Bone turnover marker data were available from patients (775/2458 [32%]) at a subset of study centers. Bone-specific alkaline phosphatase levels declined with 5-mg risedronate treatment, reaching a nadir of -35% (median percentage change from baseline) in the risedronate group at 6 months, compared with -12% in the placebo group (Figure 5). Values at the end of 3 years of treatment were –33% and –7%, respectively. Similar changes were seen in the deoxypyridinoline-creatinine ratio, which reached a nadir at 6 months of –38% in the 5-mg risedronate group compared with –8% in the placebo group and also rose by the end of the study to values of –26% and –1%, respectively (Figure 5).
|
|
|
|
Figure 5. Median Percentage Change From Baseline in Bone-Specific Alkaline Phosphatase and Deoxypyridinoline-Creatinine Ratio
|
|
|
Adverse Events
The overall incidence of adverse events was similar across treatment groups, as was the incidence of serious adverse events and the incidence of drug-related adverse events (Table 3). The proportion of subjects in the 5-mg risedronate group who withdrew from the study because of an adverse event was similar to that in the placebo group, whereas the proportion in the 2.5-mg risedronate group, which had a shorter exposure, was lower. Digestive system complaints were the most common adverse events associated with study discontinuance, accounting for 56 patients (42%) withdrawing due to adverse events in the placebo group, compared with 49 patients (36%) in the 5-mg risedronate group.
|
|
|
|
Table 3. Summary of Adverse Events by Study Group*
|
|
|
Most adverse events were reported at similar frequencies in the risedronate and placebo groups. Consistent with the efficacy findings, bone fractures reported as adverse events occurred at a lower incidence in the 5-mg risedronate group than in the placebo group (13% vs 18%; P=.009). There were no significant biochemical changes observed in renal, hepatic, or hematologic parameters in any treatment group.
Overall, the incidence of upper gastrointestinal tract adverse events in the 5-mg risedronate group was similar to that in the placebo group, and most of these events were of mild-to-moderate severity. The most common upper gastrointestinal tract adverse events were dyspepsia, abdominal pain, and gastritis. The percentage of subjects (4.2%) in the 5-mg risedronate group who underwent gastrointestinal tract endoscopy after reporting gastrointestinal adverse events was similar to that in the placebo group (3.7%), and a similar proportion of subjects in each group undergoing endoscopy had some abnormal finding (85% and 83%, respectively). More cases of duodenitis were reported in the 5-mg risedronate group compared with placebo (9 vs 2), but there were fewer cases of duodenal ulcer in the 5-mg risedronate group (1 vs 3).
Bone Safety
A total of 62 pairs of biopsy samples (baseline and end-of-study samples from the same patient) were available from 31 subjects each in the placebo and the 5-mg risedronate groups. Histologic assessment revealed normal bone with no evidence of mineralization problems or marrow abnormalities in risedronate-treated subjects. Based on histomorphometric analyses, risedronate treatment reduced bone turnover by approximately 50%, compared with no change in the placebo group. Risedronate produced a more positive bone balance at the level of the remodeling unit, while the change in the placebo group was negative (median change, +4.0 vs –4.6 µm). Cortical thickness increased slightly from baseline with risedronate treatment compared with a negative trend in the placebo group (median percentage change, risedronate, +20%; placebo, –11%). There was an increase in median cortical porosity in both groups (risedronate, 17%; placebo, 8%), likely due to the prolongation of the remodeling period. Cortical thickness and porosity data indicate that bone structure was preserved by risedronate treatment.
COMMENT
This trial demonstrates the efficacy of risedronate in the treatment of women with established postmenopausal osteoporosis. Daily oral risedronate therapy decreased the incidence of both vertebral and nonvertebral fractures and increased BMD at clinically important skeletal sites. The primary mechanism of action of risedronate is suppression of bone turnover; this action was reflected in moderate decreases in the biochemical and histomorphometric indices of turnover.
Prevention of fractures is the primary goal of osteoporosis treatment. In this study, risedronate therapy decreased the incidence of new vertebral fractures in postmenopausal women with a history of vertebral fracture. The onset of the fracture effect was rapid, with significant decreases in new vertebral fracture incidence observed within the first year. Some other osteoporosis studies have used a vertebral height loss of 20% as the criterion for vertebral fracture,9-10 as opposed to the 15% definition we used. However, in a retrospective analysis, we applied a 20% fracture criterion and obtained consistent results (data not shown). Among patients who withdrew from the study, a higher proportion of placebo-treated subjects had experienced incident vertebral fractures compared with subjects in the 5-mg risedronate group. This difference may have reduced the apparent treatment effect.
The reduction in nonvertebral fractures at skeletal sites of clinical interest indicates a beneficial effect of risedronate treatment on the peripheral skeleton. This finding is important, given the significant pain and disability associated with nonvertebral fractures in osteoporotic patients. Whereas subjects receiving risedronate experienced increases in or preservation of BMD at all sites, the placebo-treated subjects, who received a high level of calcium supplementation (1000 mg/d) and cholecalciferol, if needed, showed significant losses from baseline at the femoral neck, trochanter, and midshaft radius. These BMD findings are consistent with the observed beneficial effect of risedronate treatment on nonvertebral fracture incidence and indicate that recommended levels of calcium and cholecalciferol alone are insufficient in the treatment of this patient population.
The proportion of subjects discontinuing study participation was high, but not higher than we had anticipated in the sample size calculation and not remarkably higher than that seen in other recent osteoporosis trials.27-29 Factors that might have contributed to a high withdrawal rate include the duration of the study, the age of the subjects, and the conduct of the study at a large number of study centers. There were no evident differences between the treatment groups in the proportion of subjects discontinuing treatment or in the reasons for withdrawal. As planned, the study retained sufficient power to determine the efficacy of risedronate in preventing vertebral fractures.
A number of antiresorptive agents are reported to have antifracture efficacy in the treatment of women with postmenopausal osteoporosis. Comparisons of different agents are of much clinical interest; however, any comparison of data between studies must be viewed cautiously, due to differences in study designs and patient populations. The 2 most studied osteoporosis therapies are alendronate and risedronate. While there are differences in the magnitude of changes in BMD and biochemical markers of bone turnover observed with these 2 agents, the magnitude of the reduction in vertebral and nonvertebral fracture risk appears to be similar. This observation suggests that other effects of treatment, such as the reduction in bone turnover or changes in bone quality, may be important in the preservation of vertebral integrity.
Risedronate treatment was well tolerated in this study, with an overall safety profile similar to placebo. Upper gastrointestinal tract safety is of particular interest because of adverse effects noted during clinical use with the bisphosphonates alendronate and pamidronate.14-15,30-31 Although some studies of bisphosphonates have excluded subjects with specific gastrointestinal disorders,9-10,12 our study did not; approximately 35% of the subjects in this trial had a history of or ongoing gastrointestinal disorders at study entry. It is reassuring that the gastrointestinal safety profile of risedronate in this trial was good despite the inclusion of these subjects. Investigators were also provided with the opportunity to obtain endoscopies at their discretion in any patient with gastrointestinal complaints; these findings further support the gastrointestinal safety of risedronate. Bone safety was established by examination of the largest number of paired biopsy specimens yet reported for any osteoporosis therapy.
We conclude that oral risedronate therapy is well tolerated and produces a rapid and clinically important reduction in the risk of bone fracture in women with established postmenopausal osteoporosis. Significant reductions in the incidence of new vertebral fractures were observed in the first year of treatment, while a similar decrease in nonvertebral fractures was seen after 3 years. Risedronate is an effective and well-tolerated therapy for the treatment of postmenopausal osteoporosis.
AUTHOR INFORMATION
Members of the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group: The principal investigators at each center were: J. Adachi, MD, Hamilton, Ontario; R. Altman, MD, Miami, Fla; D. J. Appelrouth, MD, Atlanta, Ga; J. Assini, MD, Schenectady, NY; A. D. Bankhurst, MD, Department of Medicine, University of New Mexico School of Medicine, Albuquerque; M. Baron, MD, Jewish General Hospital, Montreal, Quebec; D. J. Baylink, MD, Loma Linda, Calif; N. H. Bell, MD, Veterans Affairs Medical Center, Charleston, SC; W. Bensen, MD, Hamilton, Ontario; M. B. Block, MD, Clinical Research Center, Phoenix Ariz; R. S. Bockman, MD, PhD, New York, NY; E. Boling, MD, Rancho Cucamonga, Calif; M. Bolognese, MD, Gaithersberg, Md; S. L. Bonnick, MD, Center for Research on Women's Health, Denton, Tex; S. Bowman, MD, Tampa Bay Medical Research, Clearwater, Fla; W. Briney, MD, Denver, Colo; J. Brown, MD, Hospital Center, Laval University, Sainte-Foy, Quebec; S. B. Broy, MD, Lutheran General Medical Group, Chicago, Ill; J. Cabral, MD, Cleveland Clinic Florida, Fort Lauderdale, Fla; R. B. Cannon, MD, Salt Lake Clinic Research Foundation, Salt Lake City, Utah; C. Chesnut III, MD, University of Washington, Seattle; Y. D. Coble, MD, Jacksonville, Fla; S. A. Cohen, MD, Clinical Research Consultants, Trumball, Conn; S. Cohen, MD, Metroplex Clinical Research Center, Dallas, Tex; M. Davis, MD, Coastal Clinical Research Inc, Mobile, Ala; W. Delaney, MD, Primary Care of Danbury, Danbury, Conn; G. B. Dewees, MD, SORRA Research Center, Birmingham, Ala; M. Doyle, MD, Ferndale Clinic Division, William Beaumont Hospital, Ferndale, Mich; R. D. Emkey, MD, Bone Research Center, Reading Hospital and Medical Center, Reading, Pa; S. C. English, MD, Deaconess Research Institute, Billings, Mont; M. P. Ettinger, MD, Regional Osteoporosis Center, Stuart, Fla; N. R. Farris, MD, Central Kentucky Research, Lexington; D. Freeman, MD, North Carolina Arthritis & Allergy Care Center, Raleigh; N. M. Friedman, MD, Lovelace Scientific Resources, Albuquerque, NM; A. B. Galway, MD, Department of Endocrinology, Health Science Center, St Johns, New Brunswick; M. L. S. Gass, MD, Reproductive Medical Research, Cincinnati, Ohio; H. Geisberg, MD, Anderson, SC; G. Gerety, MD, Albany, NY; M. Gittelman, MD, South Florida Medical Research, Aventura; M. Greenwald, MD, Palm Springs, Calif; R. C. Hamdy, MD, Veterans Affairs Medical Center, Mountain Home, Tenn; T. N. Hangartner, PhD, Miami Valley Hospital, Dayton, Ohio; D. A. Hanley, MD, Heritage Medical Research Center, Calgary, Alberta; T. Harrington, MD, Jackson Foundation, Madison, Wis; S. T. Harris, MD, University of California, San Francisco; D. J. Helfrich, MD, Mercy Hospital of Pittsburgh, Pittsburgh, Pa; M. Heller, MD, Arthritis Associates Inc, Peabody, Mass; M. Heur, MD, Climacteric Clinic, Gainesville, Fla; M. C. Hochberg, MD, Osteoporosis Clinic, University of Maryland, Baltimore; A. Hodsman, MD, Department of Medicine, St Joseph's Health Center, London, Ontario; R. D. Jackson, MD, Columbus, Ohio; A. J. Jacobs, MD, Arthritis Center of Nebraska, Lincoln; P. Jellinger, MD, Hollywood, Fla; C. C. Johnston, Jr, MD, Indiana University Medical Center, Indianapolis; R. Josse, MD, St Michaels Hospital, Toronto, Ontario; A. V. Jovaisas, MD, Ottawa, Ontario; J. L. Juozevicius, MD, Kalamazoo, Mich; R. A. Kaplan, MD, Concord, Calif; M. Keller, San Diego, Calif; D. L. Kendler, MD, Vancouver Hospital and Health Science Centre, Vancouver, British Columbia; R. Khairi, MD, Physicians Research Group, Indianapolis, Ind; M. S. Kipnes, MD, DGD Research, San Antonio, Tex; A. J. Kivitz, MD, Attoona, Pa; J. Kotler, MD, Department of Nuclear Medicine, Holy Cross Hospital, Fort Lauderdale, Fla; N. Koval, MD, Arthritis & Rheumatism Associates, Wheaton, Md; N. J. Kramer, MD, Charlotte, NC; A. J. Laster, MD, First Charlotte Physicians, Charlotte, NC; E. Leib, MD, Fletcher Allen Health Center, Burlington, Vt; R. M. Levy, MD, Olympia Arthritis Clinic, Olympia, Wash; A. A. Licata, MD, Cleveland Clinic Foundation, Cleveland, Ohio; R. Lies, MD, Wichita Clinic, Wichita, Kan; T. Littlejohn, MD, Piedmont Research Associates, Winston-Salem, NC; M. Lowenstein, MD, Palm Harbour, Fla; F. Maggiacomo, DO, Silver Lake Medical Inc, Providence, RI; A. Mangione, MD, Jenkintown, Pa; R. E. Marcus, MD, Rheumatology Associates of North Jersey, Teaneck, NJ; M. Maricic, MD, University of Arizona Health Sciences Center, Tucson; M. R. McClung, MD, Osteoporosis Research Center, Portland, Ore; H. H. McIlwain, MD, Tampa, Fla; C. D. McKeever, MD, reSearch for Health Inc, Houston, Tex; P. Miller, MD, Colorado Center for Bone Research, Lakewood; S. S. Miller, MD, San Antonio, Tex; A. Mulloy, MD, Medical College of Georgia, Augusta; J. A. Napier, DO, St Petersburg, Fla; L. Olanksky, MD, Oklahoma University Health Sciences Center, Oklahoma City; W. Olszynski, MD, Midtown Medical Center, Saskatoon, Saskatchewan; S. A. Pasquale, MD, Women's Health Research Section, University Hospital, New Brunswick, NJ; D. A. Podlecki, MD, Longmont Clinic, Longmont, Colo; J. J. Prendergast, MD, Pacific Medical Research Services, Atherton, Calif; H. M. Prupas, MD, Reno, Nev; S. Quandt, PhD, Department of Public Health Sciences, Bowman Gray School of Medicine, Winston-Salem, NC; R. J. Rapoport, MD, Fall River, Mass; T. Rooney, DO, Des Moines, Iowa; C. Rosen, MD, Osteoporosis Research Center, St Joseph Hospital, Bangor, Me; S. Rosenblatt, MD, Irvine, Calif; B. Samuels, MD, Stafford Medical Associates, Dover, NH; E. N. Schwartz, MD, Foundation for Osteoporosis Research & Education, Oakland, Calif; S. Scumpia, MD, Center for Clinical Research, Austin, Tex; W. J. Shergy, MD, Rheumatology Association of North Alabama, Huntsville; S. L. Silverman, MD, Osteoporosis Medical Center, Beverly Hills, Calif; C. L. Smith, MD, Bone and Mineral Metabolism Clinic, Hennepin County Medical Center, Minneapolis, Minn; L. G. Ste-Marie, MD, Centre de Recherche Andre-Viallet, Montreal, Quebec; J. L. Stock, MD, Clinical Research Office, Division of Endocrinology, Worcester, Mass; A. Tenenhouse, MD, Clinical Research Group, Montreal, Quebec; A. Virshup, MD, West Palm Beach, Fla; R. D. Wasnick, MD, Hawaii Osteoporosis Center, Honolulu; N. B. Watts, MD, Emory University, Atlanta, Ga; N. Wei, MD, Arthritis and Osteoporosis Center of Maryland, Frederick; S. R. Weiss, MD, San Diego, Calif; and T. M. Zizic, MD, Baltimore, Md.
Financial Disclosures: Dr Watts currently receives research support from Roche Pharmaceuticals, Boehringer-Mannheim, Eli Lilly and Company, Novartis Pharmaceuticals, Shick Technologies Inc, and Sunlight Ultrasound Technologies; has received honoraria for lectures in the past year from Eli Lilly and Company, Hoechst Marion Roussel, Merck, Procter & Gamble Pharmaceuticals Inc, Solvay Pharmaceuticals, and Wyeth-Ayerst Pharmaceuticals; and consulting fees in the past year from Hoechst Marion Roussel, Merck, Norland Medical Systems, and Procter & Gamble Pharmaceuticals. Dr Genant has received research support from Aloka, DMS Diagnostic Medical Systems, Hologic Inc, Eli Lilly, Lunar Corporation, Merck, Metra Biosystems, Novartis, Parke Davis, Pfizer, Procter & Gamble, Roche, SmithKline Beecham, and Sunlight; honoraria from Eli Lilly, Lunar, Merck, Novartis, Parke Davis, Pfizer, Procter & Gamble, Roche, SmithKline Beecham, and Sunlight; is on the scientific advisory boards of Parke Davis, Novartis, Eli Lilly, Merck, Metra, Sunlight, and Synarc Inc; and owns stock in Synarc. Dr McKeever has received research funding or honororia from Boehringer Mannheim, Bristol-Myers, Hoeschst Marion Roussel, Eli Lilly, Merck, Novartis, Pfizer, Procter & Gamble, Searle, and Wyeth-Ayerst. Dr Hangartner has received grants and consulting honoraria from Procter & Gamble Pharmaceuticals. Dr Keller has done clinical research for Pfizer, Merck, Searle, and Procter & Gamble; and has been on speaker's bureaus for Merck, Searle, and Procter & Gamble. Dr Chesnut has received research grants from Novartis, Zeneca, SmithKline Beecham, Berlex, and Procter & Gamble Pharmaceuticals; has received honoraria or research funding from Roche Laboratories, Wyeth-Ayerst, Procter & Gamble Pharmaceuticals, and Novartis; and is on advisory boards for Procter & Gamble Pharmaceuticals, Novartis, Roche Laboratories, and SmithKline Beecham. Dr Brown has acted as an investigator, consultant, and speaker for Procter & Gamble Pharmaceuticals. Dr Eriksen has received research grants from Novo, Procter & Gamble Pharmaceuticals, and Eli Lilly; and honoraria or research funding from Roche Laboratories, Hoechst Marion Roussel Pharmaceuticals, Eli Lilly, Merck, and Procter & Gamble Pharmaceuticals. Dr Miller has received research grants from Procter & Gamble Pharmaceuticals, Hoechst Marion Roussel Pharmaceuticals, Novartis Pharmaceuticals, Eli Lilly and Company, Upjohn, Merck, Roche Pharmaceuticals, Pfizer Pharmaceuticals, SmithKline Beecham, Novo Nordisk, Hologic Inc, Lunar Corporation, McCue Ultrasound, Metra Biosystems, and Pacific Biosystems; and is on speakers and advisory boards of Procter & Gamble Pharmaceuticals, Novartis Pharmaceuticals, Merck, and Eli Lilly and Company.
Funding/Support: This research was supported by Procter & Gamble Pharmaceuticals and Hoechst Marion Roussel.
Acknowledgment: We acknowledge David J. Valent and Lisa C. Bosch for assistance in the preparation of the manuscript. We would also like to thank Pirow Bekker, MD, PhD, for his contributions to the design and execution of this study.
Corresponding Author and Reprints: Steven T. Harris, MD, University of California, San Francisco, 350 Parnassus Ave, Suite 706, San Francisco, CA 94117-3608.
Author Affiliations: University of California, San Francisco (Drs Harris and Genant); Department of Medicine, Emory University, Atlanta, Ga (Dr Watts); reSearch for Health/Health Advance, Houston, Tex (Dr McKeever); Biomedical Imaging Laboratory, Wright State University, Dayton, Ohio (Dr Hangartner); San Diego Arthritis & Osteoporosis Medical Clinic, San Diego, Calif (Dr Keller); Department of Nuclear Medicine, University of Washington, Seattle (Dr Chesnut); Department of Rheumatology, Hospital Center, Laval University, Ste-Foy, Quebec (Dr Brown); Department of Endocrinology, Aarhus Amtssygehus, Aarhus, Denmark (Dr Eriksen); Procter & Gamble Pharmaceuticals, Cincinnati, Ohio (Drs Hoseyni and Axelrod); and Colorado Center for Bone Research, Lakewood (Dr Miller).
REFERENCES
| |
1. Lindsay R. Estrogen deficiency. In: Riggs BL, Melton LJ, eds. Osteoporosis: Etiology, Diagnosis, and Management. 2nd ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1995:133-160.
2. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
3. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR for the Study of Osteoporotic Fractures Research Group. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 1995;122:9-16.
FREE FULL TEXT
4. Barrett-Connor E. Prevalence, initiation, and continuation of hormone replacement therapy. J Womens Health. 1995;4:143-148.
5. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol. 1987;156:1332-1334.
WEB OF SCIENCE
| PUBMED
6. Ettinger B, Black D, Cummings S, et al. Raloxifene reduces the risk of incident vertebral fractures: 24-month interim analyses [abstract]. Osteoporos Int. 1998;8(suppl 3):11.
7. Ensrud K, Black D, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637-645.
FREE FULL TEXT
8. Chesnut III CH, Baylink DJ, Doyle D, et al. Salmon calcitonin nasal spray prevents vertebral fractures in established osteoporosis: further interim results of the "PROOF" study. Osteoporos Int. 1998;8(suppl 3):13.
9. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437-1443.
FREE FULL TEXT
10. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
11. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 1993;95:557-567.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
12. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
FREE FULL TEXT
13. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manage Care. 1998;4:1377-1382.
WEB OF SCIENCE
| PUBMED
14. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016-1021.
FREE FULL TEXT
15. Maconi G, Porro GB. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol. 1995;90:1889-1890.
WEB OF SCIENCE
| PUBMED
16. Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A comparative trial of risedronate versus etidronate in the treatment of patients with Paget's disease of bone. Am J Med. 1999;106:513-520.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
17. Hosking DJ, Eusebio RA, Chines AA. Paget's disease of bone: reduction of disease activity with oral risedronate. Bone. 1998;22:51-55.
PUBMED
18. Roux C, Ravaud P, Cohen-Solal M, et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone. 1994;15:41-49.
PUBMED
19. Cohen-Solal ME, Roux C, Valentin-Opran A, Dougados M, Amor B, de Vernejoul MC. Histomorphometric effect of six month treatment with oral risedronate in patients with multiple myeloma. Bone. 1993;14:505-509.
PUBMED
20. Mortensen L, Charles P, Bekker PJ, DiGennaro J, Johnston CC Jr. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab. 1998;83:396-402.
FREE FULL TEXT
21. Melton III LJ, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL. Prevalence and incidence of vertebral deformities. Osteoporos Int. 1993;3:113-119.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
22. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148.
WEB OF SCIENCE
| PUBMED
23. Genant HK, Engelke K, Fuerst T, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res. 1996;11:707-730.
WEB OF SCIENCE
| PUBMED
24. Genant HK, Grampp S, Gluer CC, et al. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res. 1994;9:1503-1514.
WEB OF SCIENCE
| PUBMED
25. Steiger P for the Committee for Standards in DXA. Standardization of postero-anterior (PA) spine BMD measurements by DXA [letter]. Bone. 1995;17:435.
PUBMED
26. Kalbfleisch JD, Prentice RL. Statistical Analysis of Failure Time Data. New York, NY: Wiley; 1980.
27. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1647.
FREE FULL TEXT
28. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone mineral density in men and women 65 years of age or older. N Engl J Med. 1997;337:670-676.
FREE FULL TEXT
29. Lips P, Graffmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial. Ann Intern Med. 1996;124:400-406.
FREE FULL TEXT
30. Spivacow FR, Zanchetta JR, Kerzberg EM, Frigerl A, Flasche R, Roldan E. Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseases. Curr Ther Res. 1996;57:123-130.
FULL TEXT
31. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int. 1994;4:320-322.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Osteoporosis: from early fracture prevention to better bone health with strontium ranelate
Cortet
Rheumatology (Oxford) 2009;48:iv14-iv19.
ABSTRACT
| FULL TEXT
Continuous broad protection against osteoporotic fractures with strontium ranelate
Ferrari
Rheumatology (Oxford) 2009;48:iv20-iv24.
ABSTRACT
| FULL TEXT
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings et al.
NEJM 2009;361:756-765.
ABSTRACT
| FULL TEXT
Interpretation of Randomized Controlled Trials of Fracture Prevention
Nguyen
IBMS BoneKEy 2009;6:279-294.
ABSTRACT
| FULL TEXT
Trends and determinants of prescription medication use for treatment of osteoporosis
Farley and Blalock
Am J Health Syst Pharm 2009;66:1191-1201.
ABSTRACT
| FULL TEXT
Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management
Kennel and Drake
Mayo Clin Proc. 2009;84:632-638.
ABSTRACT
| FULL TEXT
Prediction of Changes in Bone Mineral Density in Postmenopausal Women Treated with Once-Weekly Bisphosphonates
Burnett-Bowie et al.
J. Clin. Endocrinol. Metab. 2009;94:1097-1103.
ABSTRACT
| FULL TEXT
Risk of Severe Gastrointestinal Events in Women Treated with Monthly Ibandronate or Weekly Alendronate and Risedronate
Blumentals et al.
The Annals of Pharmacotherapy 2009;43:577-585.
ABSTRACT
| FULL TEXT
Is Monitoring Osteoporosis Therapy Worthwhile?
Compston
IBMS BoneKEy 2009;6:99-106.
ABSTRACT
| FULL TEXT
The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women
Grey et al.
J. Clin. Endocrinol. Metab. 2009;94:538-544.
ABSTRACT
| FULL TEXT
Bisphosphonates and osteonecrosis of the jaw: Innocent association or significant risk?
CAREY and PALOMO
Cleveland Clinic Journal of Medicine 2008;75:871-879.
ABSTRACT
| FULL TEXT
Osteoporosis
Davies
InnovAiT 2008;1:808-812.
ABSTRACT
| FULL TEXT
Mammalian hibernation as a model of disuse osteoporosis: the effects of physical inactivity on bone metabolism, structure, and strength
McGee-Lawrence et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008;295:R1999-R2014.
ABSTRACT
| FULL TEXT
The Role of Bone Biopsy in Patients with Chronic Renal Failure
Miller
CJASN 2008;3:S140-S150.
ABSTRACT
| FULL TEXT
Using biochemical markers of bone turnover in clinical practice
SINGER and EYRE
Cleveland Clinic Journal of Medicine 2008;75:739-750.
ABSTRACT
| FULL TEXT
Prevention, Diagnosis, and Management of Osteoporosis-Related Fracture: A Multifactoral Osteopathic Approach
Gronholz
JAOA: Journal of the American Osteopathic Association 2008;108:575-585.
ABSTRACT
| FULL TEXT
Low Incidence of Anti-Osteoporosis Treatment After Hip Fracture
Rabenda et al.
JBJS 2008;90:2142-2148.
ABSTRACT
| FULL TEXT
Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer
Lester et al.
Clin. Cancer Res. 2008;14:6336-6342.
ABSTRACT
| FULL TEXT
Bisphosphonates: Mechanism of Action and Role in Clinical Practice
Drake et al.
Mayo Clin Proc. 2008;83:1032-1045.
ABSTRACT
| FULL TEXT
A Coordinator Program in Post-Fracture Osteoporosis Management Improves Outcomes and Saves Costs
Sander et al.
JBJS 2008;90:1197-1205.
ABSTRACT
| FULL TEXT
Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons
Gehrig et al.
JBJS 2008;90:1362-1374.
FULL TEXT
Randomized Trial of Once-Weekly Parathyroid Hormone (1-84) on Bone Mineral Density and Remodeling
Black et al.
J. Clin. Endocrinol. Metab. 2008;93:2166-2172.
ABSTRACT
| FULL TEXT
Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Greenspan et al.
JCO 2008;26:2644-2652.
ABSTRACT
| FULL TEXT
Update on the treatment of post-menopausal osteoporosis
Cole et al.
Br Med Bull 2008;86:129-143.
ABSTRACT
| FULL TEXT
Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate
Papapoulos and Schimmer
Postgrad. Med. J. 2008;84:307-312.
ABSTRACT
| FULL TEXT
Osteoporosis and Its Implications for Dental Patients
Edwards and Migliorati
Journal of the American Dental Association 2008;139:545-552.
ABSTRACT
| FULL TEXT
Clinical Pharmacists' Role in Improving Osteoporosis Treatment Rates Among Elderly Patients with Untreated Atraumatic Fractures
Nadrash et al.
The Annals of Pharmacotherapy 2008;42:334-340.
ABSTRACT
| FULL TEXT
ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults
MacLaughlin and Raehl
Am J Health Syst Pharm 2008;65:343-357.
FULL TEXT
Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial
Grbic et al.
Journal of the American Dental Association 2008;139:32-40.
ABSTRACT
| FULL TEXT
Long-term Risk of Incident Vertebral Fractures
Cauley et al.
JAMA 2007;298:2761-2767.
ABSTRACT
| FULL TEXT
Telephone Counseling to Improve Osteoporosis Treatment Adherence: An Effectiveness Study in Community Practice Settings
Cook et al.
American Journal of Medical Quality 2007;22:445-456.
ABSTRACT
Is Radiographic Vertebral Fracture a Risk Factor for Mortality?
Trone et al.
Am J Epidemiol 2007;166:1191-1197.
ABSTRACT
| FULL TEXT
Development and Internal Validation of the Male Osteoporosis Risk Estimation Score
Shepherd et al.
Ann Fam Med 2007;5:540-546.
ABSTRACT
| FULL TEXT
Bisphosphonate Treatment and Fracture Repair
McDonald et al.
IBMS BoneKEy 2007;4:236-251.
ABSTRACT
| FULL TEXT
Yearly zoledronic acid in postmenopausal osteoporosis.
de Nijs et al.
NEJM 2007;357:711-712.
FULL TEXT
Relationship between Bone Mineral Density Changes and Fracture Risk Reduction in Patients Treated with Strontium Ranelate
Bruyere et al.
J. Clin. Endocrinol. Metab. 2007;92:3076-3081.
ABSTRACT
| FULL TEXT
The role of DXA bone density scans in the diagnosis and treatment of osteoporosis
Blake and Fogelman
Postgrad. Med. J. 2007;83:509-517.
ABSTRACT
| FULL TEXT
Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate
Papapoulos and Schimmer
Ann Rheum Dis 2007;66:853-858.
ABSTRACT
| FULL TEXT
Assessment of non-vertebral fracture risk in postmenopausal women
Roux et al.
Ann Rheum Dis 2007;66:931-935.
ABSTRACT
| FULL TEXT
Review of Postmenopausal Osteoporosis Pharmacotherapy
Mayes
Nutr Clin Pract 2007;22:276-285.
ABSTRACT
| FULL TEXT
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black et al.
NEJM 2007;356:1809-1822.
ABSTRACT
| FULL TEXT
Americans are not meeting current calcium recommendations
Ma et al.
Am. J. Clin. Nutr. 2007;85:1361-1366.
ABSTRACT
| FULL TEXT
Risedronate or Alendronate for the Prevention of Osteoporotic Fractures: Is There a REAL Difference?
Ferrari and Rizzoli
IBMS BoneKEy 2007;4:141-143.
FULL TEXT
Effect of Monitoring Bone Turnover Markers on Persistence with Risedronate Treatment of Postmenopausal Osteoporosis
Delmas et al.
J. Clin. Endocrinol. Metab. 2007;92:1296-1304.
ABSTRACT
| FULL TEXT
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease
Sato et al.
Neurology 2007;68:911-915.
ABSTRACT
| FULL TEXT
Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Randomized Trial
Greenspan et al.
ANN INTERN MED 2007;146:326-339.
ABSTRACT
| FULL TEXT
Monitoring Cancer Treatment with PET/CT: Does It Make a Difference?
Weber and Figlin
JNM 2007;48:36S-44S.
ABSTRACT
| FULL TEXT
Effects of Continuing or Stopping Alendronate After 5 Years of Treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A Randomized Trial
Black et al.
JAMA 2006;296:2927-2938.
ABSTRACT
| FULL TEXT
Osteoporosis and its management
Poole and Compston
BMJ 2006;333:1251-1256.
FULL TEXT
Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO)
Jakob et al.
QJM 2006;99:531-543.
ABSTRACT
| FULL TEXT
A New Look at Osteoporosis Outcomes: The Influence of Treatment, Compliance, Persistence, and Adherence
Badamgarav and Fitzpatrick
Mayo Clin Proc. 2006;81:1009-1012.
FULL TEXT
Adherence to Bisphosphonate Therapy and Fracture Rates in Osteoporotic Women: Relationship to Vertebral and Nonvertebral Fractures From 2 US Claims Databases
Siris et al.
Mayo Clin Proc. 2006;81:1013-1022.
ABSTRACT
| FULL TEXT
Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis.
Hodsman et al.
CMAJ 2006;175:48-48.
FULL TEXT
Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years
Bonnick et al.
J. Clin. Endocrinol. Metab. 2006;91:2631-2637.
ABSTRACT
| FULL TEXT
The Cost-effectiveness of Therapy With Teriparatide and Alendronate in Women With Severe Osteoporosis.
Liu et al.
Arch Intern Med 2006;166:1209-1217.
ABSTRACT
| FULL TEXT
Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis.
Nayak et al.
ANN INTERN MED 2006;144:832-841.
ABSTRACT
| FULL TEXT
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
Reginster et al.
Ann Rheum Dis 2006;65:654-661.
ABSTRACT
| FULL TEXT
Cancer-treatment-induced bone loss, part 2
Michaud and Goodin
Am J Health Syst Pharm 2006;63:534-546.
ABSTRACT
| FULL TEXT
Knowledge and Opinions of Orthopaedic Surgeons Concerning Medical Evaluation and Treatment of Patients with Osteoporotic Fracture
Skedros et al.
JBJS 2006;88:18-24.
ABSTRACT
| FULL TEXT
Effective Initiation of Osteoporosis Diagnosis and Treatment for Patients with a Fragility Fracture in an Orthopaedic Environment
Bogoch et al.
JBJS 2006;88:25-34.
ABSTRACT
| FULL TEXT
The prevention of osteoporotic fractures
Karlsson et al.
J Bone Joint Surg Br 2005;87-B:1320-1327.
FULL TEXT
Alendronate and Vertebral Fracture Risk-Reply-I
Quandt et al.
Mayo Clin Proc. 2005;80:1238-1240.
Efficacy and Tolerability of Alendronate Once Weekly in Asian Postmenopausal Osteoporotic Women
Ho and Kung
The Annals of Pharmacotherapy 2005;39:1428-1433.
ABSTRACT
| FULL TEXT
Daily and Cyclic Parathyroid Hormone in Women Receiving Alendronate
Cosman et al.
NEJM 2005;353:566-575.
ABSTRACT
| FULL TEXT
Postmenopausal Osteoporosis
Rosen
NEJM 2005;353:595-603.
FULL TEXT
Risedronate Sodium Therapy for Prevention of Hip Fracture in Men 65 Years or Older After Stroke
Sato et al.
Arch Intern Med 2005;165:1743-1748.
ABSTRACT
| FULL TEXT
Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass
McClung et al.
Arch Intern Med 2005;165:1762-1768.
ABSTRACT
| FULL TEXT
Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use
Hodsman et al.
Endocr. Rev. 2005;26:688-703.
ABSTRACT
| FULL TEXT
Strontium ranelate for the treatment of osteoporosis
Fogelman and Blake
BMJ 2005;330:1400-1401.
FULL TEXT
Strontium Ranelate Reduces the Risk of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study
Reginster et al.
J. Clin. Endocrinol. Metab. 2005;90:2816-2822.
ABSTRACT
| FULL TEXT
Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates
Licata
The Annals of Pharmacotherapy 2005;39:668-677.
ABSTRACT
| FULL TEXT
The Roles of Bone Mineral Density, Bone Turnover, and Other Properties in Reducing Fracture Risk During Antiresorptive Therapy
Epstein
Mayo Clin Proc. 2005;80:379-388.
ABSTRACT
Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus
Mok et al.
Lupus 2005;14:106-112.
ABSTRACT
Association between Screening for Osteoporosis and the Incidence of Hip Fracture
Kern et al.
ANN INTERN MED 2005;142:173-181.
ABSTRACT
| FULL TEXT
Bone Density Screening: A New Level of Evidence?
Cummings
ANN INTERN MED 2005;142:217-219.
FULL TEXT
Medication Use Patterns for Osteoporosis: An Assessment of Guidelines, Treatment Rates, and Quality Improvement Interventions
Solomon et al.
Mayo Clin Proc. 2005;80:194-202.
ABSTRACT
Long-Term Therapy of Osteoporosis with Bisphosphonates: Evidence and Implications for Daily Practice
Papapoulos
IBMS BoneKEy 2005;2:13-19.
FULL TEXT
Extemporaneous Procedures for Dissolving Risedronate Tablets for Oral Administration and for Feeding Tubes
Dansereau and Crail
The Annals of Pharmacotherapy 2005;39:63-67.
ABSTRACT
| FULL TEXT
Recommendations for Optimal Care of the Fragility Fracture Patient to Reduce the Risk of Future Fracture
Bouxsein et al.
J Am Acad Orthop Surg 2004;12:385-395.
ABSTRACT
| FULL TEXT
Medication Undertreatment in Assisted Living Settings
Sloane et al.
Arch Intern Med 2004;164:2031-2037.
ABSTRACT
| FULL TEXT
A Controlled Trial To Increase Detection and Treatment of Osteoporosis in Older Patients with a Wrist Fracture
Majumdar et al.
ANN INTERN MED 2004;141:366-373.
ABSTRACT
| FULL TEXT
Classification Algorithms for Hip Fracture Prediction Based on Recursive Partitioning Methods
Jin et al.
Med Decis Making 2004;24:386-398.
ABSTRACT
National Trends in Osteoporosis Visits and Osteoporosis Treatment, 1988-2003
Stafford et al.
Arch Intern Med 2004;164:1525-1530.
ABSTRACT
| FULL TEXT
Pharmaceutical treatment of symptomatic vertebral fractures in primary care
Torgerson et al.
Ann Rheum Dis 2004;63:853-856.
ABSTRACT
| FULL TEXT
Osteoporosis Screening: Time to Take Responsibility
Mazanec
Arch Intern Med 2004;164:1047-1048.
FULL TEXT
Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures
Siris et al.
Arch Intern Med 2004;164:1108-1112.
ABSTRACT
| FULL TEXT
A Comparison of the Effects of Raloxifene and Conjugated Equine Estrogen on Bone and Lipids in Healthy Postmenopausal Women
Reid et al.
Arch Intern Med 2004;164:871-879.
ABSTRACT
| FULL TEXT
Clinical Considerations in Premenopausal Osteoporosis
Gourlay and Brown
Arch Intern Med 2004;164:603-614.
ABSTRACT
| FULL TEXT
Parathyroid Hormone
Madore et al.
J Am Acad Orthop Surg 2004;12:67-71.
FULL TEXT
Acute and long-term management of patients with vertebral fractures
Francis et al.
QJM 2004;97:63-74.
ABSTRACT
| FULL TEXT
The patient with a fragility fracture: an evolving role for the orthopaedic surgeon
Schnitzer and Wehren
QJM 2004;97:101-104.
ABSTRACT
| FULL TEXT
Underreporting of Vertebral Fractures on Routine Chest Radiography
Kim et al.
Am. J. Roentgenol. 2004;182:297-300.
ABSTRACT
| FULL TEXT
Self reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables
Orstavik et al.
Ann Rheum Dis 2004;63:177-182.
ABSTRACT
| FULL TEXT
A randomised controlled trial of standing programme on bone mineral density in non-ambulant children with cerebral palsy
Caulton et al.
Arch. Dis. Child. 2004;89:131-135.
ABSTRACT
| FULL TEXT
Efficacy and Safety of Human Parathyroid Hormone-(1-84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis
Hodsman et al.
J. Clin. Endocrinol. Metab. 2003;88:5212-5220.
ABSTRACT
| FULL TEXT
Aging Bone and Osteoporosis: Strategies for Preventing Fractures in the Elderly
Ettinger
Arch Intern Med 2003;163:2237-2246.
ABSTRACT
| FULL TEXT
|
